CAS 2133017-36-2

Formule : C19H17F2N3O3

InChI : InChI=1S/C19H17F2N3O3/c1-5-8-22-19(27)17(25)15-10(2)16(24(4)11(15)3)18(26)23-12-6-7-13(20)14(21)9-12/h1,6-7,9H,8H2,2-4H3,(H,22,27)(H,23,26)

Code InChI : SQOFSIXYJGPNKV-UHFFFAOYSA-N

SMILES : CC1=C(N(C(=C1C(=O)C(=O)NCC#C)C)C)C(=O)NC2=CC(=C(C=C2)F)F

GLP-26

CAS : 2133017-36-2

GLP-26, a CAM, blocks HBV by disrupting RNA encapsidation, reducing cccDNA >90% at 1μM, IC50=3nM in Hep AD38.

Formule : C₁₉H₁₇F₂N₃O₃

Degré de pureté : 98.62%

Couleur et forme : Solid

Masse moléculaire : 373.3534

Ref: TM-T11409

GLP-26

CAS : 2133017-36-2

GLP-26

Formule : C₁₉H₁₇F₂N₃O₃

Degré de pureté : ≥95%

Masse moléculaire : 373.35

Ref: 54-BUP09298

GLP-26

CAS : 2133017-36-2

Formule : C₁₉H₁₇F₂N₃O₃

Masse moléculaire : 373.3534

Ref: IN-DA01V54C

GLP-26

CAS : 2133017-36-2

GLP-26 is a pegylated peptide that inhibits viral replication and has life-threatening treatments. GLP-26 is a modified version of the human growth hormone (hGH) with a 24 amino acid sequence. It has been shown to inhibit the replication of the Human Immunodeficiency Virus (HIV) in culture. GLP-26 is also being studied as a potential treatment for hepatitis C, with promising results in animal models. GLP-26 has been optimized by substituting serine residues with glycine residues, which may increase its stability and bioavailability.

Formule : C₁₉H₁₇F₂N₃O₃

Degré de pureté : Min. 95%

Masse moléculaire : 373.4 g/mol

Ref: 3D-IKD01736